Disease-modifying effects of ranibizumab for central retinal vein occlusion.

ABSTRACT:

Purpose

To identify anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion (CRVO) to determine any potential underlying disease modification that occurs with anti-vascular endothelial growth factor (anti-VEGF) therapy beyond best-corrected visual acuity and central optical coherence tomography outcomes.

Methods

A post hoc analysis of a double-masked, multicenter, randomized clinical trial was performed. A total of 392 patients with macular edema after CRVO were randomized 1:1:1 to receive monthly intraocular injections of 0.3 or 0.5 mg of ranibizumab or sham injections. Central reading center-read data were reviewed to explore potential anatomic endpoints altered by therapy.

Results

At 6 months, there was a reduction in the ranibizuma

SUBMITTER: Huang JM 

PROVIDER: S-EPMC8850212 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature